Immunohistochemistry for BTK has shown staining in the immune cells within the cHL microenvironment without staining the Reed Sternberg (RS) cells themselves [18], suggesting that BTKi therapy in cHL may play a role in modulation of the immune microenvironment rather than being directly cytotoxic to RS cells themselves. The gene discussed is BTK; the disease is classic Hodgkin lymphoma.